Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

Balstilimab (antiprogrammed death-1) and zalifrelimab (anticytotoxic T-lymphocyte-associated antigen-4) are two new checkpoint inhibitors emerging as promising investigational agents for the treatment of advanced cervical cancer. This phase II trial (ClinicalTrials.gov identifier: NCT03495882) evalu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology Jg. 40; H. 7; S. 762
Hauptverfasser:	O'Malley, David M, Neffa, Maryna, Monk, Bradley J, Melkadze, Tamar, Huang, Marilyn, Kryzhanivska, Anna, Bulat, Iurie, Meniawy, Tarek M, Bagameri, Andrea, Wang, Edward W, Doger de Speville Uribe, Bernard, Hegg, Roberto, Ortuzar Feliu, Waldo, Ancukiewicz, Marek, Lugowska, Iwona
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.03.2022
Schlagworte:	Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use CTLA-4 Antigen - antagonists & inhibitors Female Follow-Up Studies Humans Immune Checkpoint Inhibitors - therapeutic use Middle Aged Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - immunology Neoplasm Recurrence, Local - pathology Prognosis Programmed Cell Death 1 Receptor - antagonists & inhibitors Survival Rate Uterine Cervical Neoplasms - drug therapy Uterine Cervical Neoplasms - immunology Uterine Cervical Neoplasms - pathology Young Adult
ISSN:	1527-7755, 1527-7755
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!